Search

Your search keyword '"Crawley, Charles"' showing total 123 results
Start Over Author "Crawley, Charles" Search Limiters Academic (Peer-Reviewed) Journals
123 results on '"Crawley, Charles"'

1. Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transplantation – a registry study on behalf of the EBMT Acute Leukemia Working Party

Author

Duque-Afonso, Jesús, Finke, Jürgen, Ngoya, Maud, Galimard, Jacques-Emmanuel, Craddock, Charles, Raj, Kavita, Bloor, Adrian, Nicholson, Emma, Eder, Matthias, Kim, Orchard, Valerius, Thomas, Snowden, John A., Tholouli, Eleni, Crawley, Charles, Collin, Matthew, Wilson, Keith M. O., Gadisseur, Alain, Protheroe, Rachel, Wagner-Drouet, Eva Maria, Savani, Bipin N., Spyridonidis, Alexandros, Ciceri, Fabio, Nagler, Arnon, and Mohty, Mohamad

Published
2024
Full Text
View/download PDF

2. Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML/MDS

Author

Loke, Justin, McCarthy, Nicholas, Jackson, Aimee, Siddique, Shamyla, Hodgkinson, Andrea, Mason, John, Crawley, Charles, Gilleece, Maria, Peniket, Andrew, Protheroe, Rachel, Salim, Rahuman, Tholouli, Eleni, Wilson, Keith, Andrew, Georgia, Dillon, Richard, Khan, Naeem, Potter, Victoria, Krishnamurthy, Pramila, Craddock, Charles, and Freeman, Sylvie

Published
2023
Full Text
View/download PDF

3. Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT

Author

Drozd-Sokołowska, Joanna, Gras, Luuk, Zinger, Nienke, Snowden, John A., Arat, Mutlu, Basak, Grzegorz, Pouli, Anastasia, Crawley, Charles, Wilson, Keith M. O., Tilly, Herve, Byrne, Jennifer, Bulabois, Claude Eric, Passweg, Jakob, Ozkurt, Zubeyde Nur, Schroyens, Wilfried, Lioure, Bruno, Colorado Araujo, Mercedes, Poiré, Xavier, Van Gorkom, Gwendolyn, Gurman, Gunhan, de Wreede, Liesbeth C., Hayden, Patrick J., Beksac, Meral, Schönland, Stefan O., and Yakoub-Agha, Ibrahim

Published
2022
Full Text
View/download PDF

4. Legionellosis after hematopoietic stem cell transplantation

Author

Mikulska, Malgorzata, Tridello, Gloria, Hoek, Jennifer, Gil, Lidia, Yañez, Lucrecia, Labussière-Wallet, Hélène, Passweg, Jakob, Xhaard, Aliénor, Pioltelli, Pietro, Caillot, Denis, Michel, Gerard, Veelken, Hendrik, Blaise, Didier, Bruno, Benedetto, Garcia, Carmen Botella, Itälä-Remes, Maija, Crawley, Charles, Bourhis, Jean Henri, Kaare, Ain, Arcese, William, Parody, Rocio, and Styczynski, Jan

Published
2021
Full Text
View/download PDF

5. Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT

Author

Eyre, Toby A., Caillard, Sophie, Finel, Herve, Boumendil, Ariane, Kothari, Jaimal, Zimmermann, Heiner, Trappe, Ralf Ulrich, De Wilde, Virginie, Tholouli, Eleni, Kanfer, Edward, Broom, Angus, Damaj, Gandhi, Bargetzi, Mario, Kozák, Tomáš, Hilgendorf, Inken, Crawley, Charles, Kerre, Tessa, Trněný, Marek, Bachy, Emmanuel, Robinson, Stephen, and Montoto, Silvia

Published
2021
Full Text
View/download PDF

7. Real‐world efficacy of single‐agent belantamab mafodotin in relapsed systemic AL amyloidosis.

Author

Khwaja, Jahanzaib, Bomsztyk, Joshua, Atta, Maria, Bygrave, Ceri, Forbes, Adam, Durairaj, Senthil, Fernandes, Savio, Taylor, James, Paterson, Pamela, Brearton, Gillian, Crawley, Charles, Sheehy, Oonagh, Brown, Rachel, Soutar, Richard, Garg, Mamta, Rydzewski, Andrzej, Jamroziak, Krzysztof, Mahmood, Shameem, and Wechalekar, Ashutosh D.

Subjects
PLASMA cell diseases, AMYLOIDOSIS, ANTIBODY-drug conjugates
Abstract

Summary: Systemic light chain (AL) amyloidosis is a relapsing plasma cell disorder. Therapy is limited, particularly for triple‐class refractory disease. We report the use of belantamab mafodotin, a BCMA‐directed drug–antibody conjugate, for relapsed AL amyloidosis, including patients traditionally excluded from clinical trials. Thirty‐one patients were reviewed, with a median of three prior lines of therapy. The median follow‐up was 12 months (95% CI 4–19), and a median of five doses were delivered. The best haematological overall response rate was 71%, and the complete/very good partial response was 58%. Sixty‐eight percent had keratopathy and improved in all. Belantamab mafodotin has high efficacy and good tolerability in patients with relapsed AL amyloidosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study

Author

Petersdorf, Effie W, Carrington, Mary, O'hUigin, Colm, Bengtsson, Mats, De Santis, Dianne, Dubois, Valerie, Gooley, Ted, Horowitz, Mary, Hsu, Katharine, Madrigal, J Alejandro, Maiers, Martin, Malkki, Mari, McKallor, Caroline, Morishima, Yasuo, Oudshoorn, Machteld, Spellman, Stephen, Villard, Jean, Stevenson, Phil, Apperley, Jane, Bardy, Peter, Bernard, Ghislaine, Bertrand, Yves, Bloor, Adrian, Bonini, Chiara, Buhler, Stephane, Bungener, Laura, Campbell, Helen, Carlson, Kristina, Carpenter, Ben, Cesbron, Anne, Chabannon, Christian, Chalandon, Yves, Chapman, Jeremy, Chebel, Réda, Chevallier, Patrice, Choi, Gerda, Collin, Matt, Cornelissen, Jan J, Crawley, Charles, D'Orsogna, Lloyd, Dalle, Jean-Hugues, Deconinck, Eric, DeMatteis, Muriel, Diviney, Mary, Dormoy, Anne, Gagne, Katia, Gibson, Brenda, Gilleece, Maria, Gottlieb, David, Gribben, John, Güngör, Tayfun, Haagenson, Mike, Hart, Cathie, Holdsworth, Rhonda, Humphreys, Ian, Kodera, Yoshihisa, Koh, Mickey, Labussière-Wallet, Hélène, Lankester, Arjan C, Lardy, Neubery, Lawson, Sarah, Leleu, Xavier, MacKinnon, Stephen, Malladi, Ram, Marsh, Steven GE, Martin, Murray, Mayor, Neema P, McQuaker, I Grant, Meijer, Ellen, Morishima, Satoko, Nikolousis, Emmanouil, Orchard, Kim, Passweg, Jacob, Patel, Amit, Patrick, Katherine, Pedron, Béatrice, Peniket, Andy, Perry, Julia, Petersen, Eefke, Potter, Victoria, Potter, Mike, Protheroe, Rachel, Raus, Nicole, Ruiz de Elvira, Carmen, Russell, Nigel, Schaap, Nicholaas PM, Schanz, Urs, Schouten, Harry, Skinner, Roderick, Snowden, John, Spierings, Eric, Steward, Colin, Tholouli, Eleni, Thornton, Alycia, Tilanus, Marcel, van de Meer, Arnold, Veelkens, Hendrik, Veys, Paul, Watson, Narelle, Weston, Lyanne, Wilson, Keith, Wilson, Marie, Wynn, Robert, Zsiros, József, Maiers, Martin J, and Spellman, Stephen R

Published
2020
Full Text
View/download PDF

9. Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT

Author

Gilleece, Maria H., Labopin, Myriam, Savani, Bipin N., Yakoub-Agha, Ibrahim, Socié, Gerard, Gedde-Dahl, Tobias, Blaise, Didier, Byrne, Jennifer L., Craddock, Charles, Cornelissen, Jan J., Arcese, William, Forcade, Edouard, Crawley, Charles, Polge, Emmanuelle, Mohty, Mohamad, and Nagler, Arnon

Published
2020
Full Text
View/download PDF

10. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Author

Chapman, Michael A., Sive, Jonathan, Ambrose, John, Roddie, Claire, Counsell, Nicholas, Lach, Anna, Abbasian, Mahnaz, Popat, Rakesh, Cavenagh, Jamie D., Oakervee, Heather, Streetly, Matthew J., Schey, Stephen, Koh, Mickey, Willis, Fenella, Virchis, Andres E., Crowe, Josephine, Quinn, Michael F., Cook, Gordon, Crawley, Charles R., Pratt, Guy, Cook, Mark, Braganza, Nivette, Adedayo, Toyin, Smith, Paul, Clifton-Hadley, Laura, Owen, Roger G., Sonneveld, Pieter, Keats, Jonathan J., Herrero, Javier, and Yong, Kwee

Published
2018
Full Text
View/download PDF

11. Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation : A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation

Author

Cesaro, Simone, Tridello, Gloria, Blijlevens, Nicole, Ljungman, Per, Craddock, Charles, Michallet, Mauricette, Martin, Alexander, Snowden, John A., Mohty, Mohamad, Maertens, Johan, Passweg, Jacob, Petersen, Eefke, Nihtinen, Anne, Isaksson, Cecilia, Milpied, Noel, Rohlich, Pierre-Simon, Deconinck, Eric, Crawley, Charles, Ledoux, Marie-Pierre, Hoek, Jennifer, Nagler, Arnon, and Styczynski, Jan

Published
2018

12. Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT.

Author

Wieczorek, Michele, Labopin, Myriam, Castagna, Luca, Brissot, Eolia, Socié, Gerard, Raiola, Anna Maria, Angelucci, Emanuele, Rodríguez, Arancha Bermúdez, Yakoub‐Agha, Ibrahim, Aljurf, Mahmoud, Crawley, Charles, Mear, Jean Baptiste, Musso, Maurizio, Fanin, Renato, Avenoso, Daniele, Turlure, Pascal, Tecchio, Cristina, Sanz, Jaime, Ciceri, Fabio, and Nagler, Arnon

Published
2023
Full Text
View/download PDF

13. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

Author

Mounier, Nicolas, Canals, Carmen, Gisselbrecht, Christian, Cornelissen, Jan, Foa, Roberto, Conde, Eulogio, Maertens, John, Attal, Michel, Rambaldi, Alessandro, Crawley, Charles, Luan, Jian-Jian, Brune, Mats, Wittnebel, Sebastian, Cook, Gordon, van Imhoff, G.W., Pfreundschuh, Michael, and Sureda, Anna

Published
2012
Full Text
View/download PDF

14. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)

Author

Goodyear, Oliver C., Dennis, Mike, Jilani, Nadira Y., Loke, Justin, Siddique, Shamyla, Ryan, Gordon, Nunnick, Jane, Khanum, Rahela, Raghavan, Manoj, Cook, Mark, Snowden, John A., Griffiths, Mike, Russell, Nigel, Yin, John, Crawley, Charles, Cook, Gordon, Vyas, Paresh, Moss, Paul, Malladi, Ram, and Craddock, Charles F.

Published
2012
Full Text
View/download PDF

16. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols

Author

Hough, Rachael, Danby, Robert, Russell, Nigel, Marks, David, Veys, Paul, Shaw, Bronwen, Wynn, Rob, Vora, Ajay, Mackinnon, Stephen, Peggs, Karl S., Crawley, Charles, Craddock, Charlie, Pagliuca, Antonio, Cook, Gordon, Snowden, John A., Clark, Andrew, Marsh, Judith, Querol, Sergio, Parkes, Guy, Braund, Henny, and Rocha, Vanderson

Published
2016
Full Text
View/download PDF

17. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

Author

Chakraverty, Ronjon, Orti, Guillermo, Roughton, Michael, Shen, Jun, Fielding, Adele, Kottaridis, Panagiotis, Milligan, Donald, Collin, Matthew, Crawley, Charles, Johnson, Peter, Clark, Andrew, Parker, Anne, Bloor, Adrian, Pettengell, Ruth, Snowden, John, Pettitt, Andrew, Clark, Richard, Hale, Geoff, Peggs, Karl, Thomson, Kirsty, Morris, Emma, and Mackinnon, Stephen

Published
2010
Full Text
View/download PDF

18. From Charts to Glyphs: Rudolf Modley's Contribution to Visual Communication.

Author

Crawley, Charles R.

Abstract

Suggests that visual communicators have much to learn from Rudolf Modley, who designed many pictorial symbols in the 1930s and 1940s worthy of study. Argues that his call for an international system of symbols is as pressing and pertinent today as it was when he made it over 20 years ago. (SR)

Published
1994

22. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT

Author

Crawley, Charles, Szydlo, Richard, Lalancette, Marc, Bacigalupo, Andrea, Lange, Andrzej, Brune, Mats, Juliusson, Gunnar, Nagler, Arnon, Gratwohl, Alois, Passweg, Jakob, Komarnicki, Mieczysław, Vitek, Antonin, Mayer, Jiri, Zander, Axel, Sierra, Jorge, Rambaldi, Alessandro, Ringden, Olle, Niederwieser, Dietger, and Apperley, Jane F.

Published
2005
Full Text
View/download PDF

28. The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

Author

Samson Rebecca S, Tozer Daniel J, Wheeler-Kingshott Claudia AM, Webber Daniel J, Barber Kelly, Richardson Karen, He Xiao-Ling, Crawley Charles, Scott Michael A, Patani Rickie, Kolappan Madhan, Connick Peter, Thomas David L, Du Ming-Qing, Luan Shi L, Michell Andrew W, Altmann Daniel R, Thompson Alan J, Miller David H, Compston Alastair, and Chandran Siddharthan

Subjects
Medicine (General), R5-920
Abstract

Abstract Background No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform the wider challenge of designing early phase clinical trials to evaluate putative neuroprotective therapies in progressive MS. Illustrated by the MSCIMS trial protocol, we describe a novel methodology based on detailed assessment of the anterior visual pathway as a model of wider disease processes - the "sentinel lesion approach". Methods/design MSCIMS is a phase IIA study of autologous mesenchymal stem cells (MSCs) in secondary progressive MS. A pre-test : post-test design is used with healthy controls providing normative data for inter-session variability. Complementary eligibility criteria and outcomes are used to select participants with disease affecting the anterior visual pathway. Results Ten participants with MS and eight healthy controls were recruited between October 2008 and March 2009. Mesenchymal stem cells were successfully isolated, expanded and characterised in vitro for all participants in the treatment arm. Conclusions In addition to determining the safety and feasibility of the intervention and informing design of future studies to address efficacy, MSCIMS adopts a novel strategy for testing neuroprotective agents in MS - the sentinel lesion approach - serving as proof of principle for its future wider applicability. Trial registration ClinicalTrials.gov (NCT00395200).

Published
2011
Full Text
View/download PDF

29. Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.

Author

Craddock, Charles, Jackson, Aimee, Loke, Justin, Siddique, Shamyla, Hodgkinson, Andrea, Mason, John, Andrew, Georgia, Nagra, Sandeep, Malladi, Ram, Peniket, Andrew, Gilleece, Maria, Salim, Rahuman, Tholouli, Eleni, Potter, Victoria, Crawley, Charles, Wheatley, Keith, Protheroe, Rachel, Vyas, Paresh, Hunter, Ann, and Parker, Anne

Published
2021
Full Text
View/download PDF

35. A One Health Study of the Genetic Relatedness of Klebsiella pneumoniae and Their Mobile Elements in the East of England.

Author

Ludden, Catherine, Moradigaravand, Danesh, Jamrozy, Dorota, Gouliouris, Theodore, Blane, Beth, Naydenova, Plamena, Hernandez-Garcia, Juan, Wood, Paul, Hadjirin, Nazreen, Radakovic, Milorad, Crawley, Charles, Brown, Nicholas M, Holmes, Mark, Parkhill, Julian, and Peacock, Sharon J

Subjects
BLOOD testing, FECAL analysis, BLOODBORNE infections, CATTLE, CEPHALOSPORINS, INFECTIOUS disease transmission, CROSS infection, DRUG resistance in microorganisms, ECOLOGY, HEMATOLOGY, HOSPITAL wards, MEDICAL research, PNEUMONIA, POPULATION geography, POULTRY, PUBLIC health surveillance, WASTE recycling, SEWAGE, SURVEYS, GENOMICS, CROSS-sectional method, DESCRIPTIVE statistics, CATHETER-related infections, KLEBSIELLA infections, BACTERIAL contamination
Abstract

Background Klebsiella pneumoniae is a human, animal, and environmental commensal and a leading cause of nosocomial infections, which are often caused by multiresistant strains. We evaluate putative sources of K. pneumoniae that are carried by and infect hospital patients. Methods We conducted a 6-month survey on 2 hematology wards at Addenbrooke's Hospital, Cambridge, United Kingdom, in 2015 to isolate K. pneumoniae from stool, blood, and the environment. We conducted cross-sectional surveys of K. pneumoniae from 29 livestock farms, 97 meat products, the hospital sewer, and 20 municipal wastewater treatment plants in the East of England between 2014 and 2015. Isolates were sequenced and their genomes compared. Results Klebsiella pneumoniae was isolated from stool of 17/149 (11%) patients and 18/922 swabs of their environment, together with 1 bloodstream infection during the study and 4 others over a 24-month period. Each patient carried 1 or more lineages that was unique to them, but 2 broad environmental contamination events and patient–environment transmission were identified. Klebsiella pneumoniae was isolated from cattle, poultry, hospital sewage, and 12/20 wastewater treatment plants. There was low genetic relatedness between isolates from patients/their hospital environment vs isolates from elsewhere. Identical genes encoding cephalosporin resistance were carried by isolates from humans/environment and elsewhere but were carried on different plasmids. Conclusion We identified no patient-to-patient transmission and no evidence for livestock as a source of K. pneumoniae infecting humans. However, our findings reaffirm the importance of the hospital environment as a source of K. pneumoniae associated with serious human infection. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

39. Correspondence

Author

Crawley, Charles R., Sachs, Irv, Wallia, C.J., Morris, Denise R., Wilkins, Teri, Quinn, Heidi, Steehouder, Michael F., Wersan, Fred, Merrill, Carla Kary, Duprey, Scott F., VanDeWeghe, Richard, Smudde, Peter M., Levinson, Mark L., Hart, Geoff, Prekeges, James, Stimely, Gwen L., Nadziejka, David E., Brandt, Linda Jay, and Smith, Susan E.

Published
1993

40. Artline 2.0

Author

Crawley, Charles R.

Published
1991

Catalog

Books, media, physical & digital resources
See catalog results